Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 19/20 | 0.94 |
| ▸ | CNR1 | P21554 | 12/20 | 0.94 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.94 |
| ▸ | LDHA | P00338 | 2/20 | 0.94 |
| ▸ | PPARG | P37231 | 1/20 | 0.94 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.94 |
| ▸ | ABHD12 | Q8N2K0 | 3/20 | 0.60 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.60 |
| ▸ | FAAH | O00519 | 2/20 | 0.60 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.60 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.60 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.60 |
| ▸ | GPR183 | P32249 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.60 |
| ▸ | GPR18 | Q14330 | 1/20 | 0.60 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.57 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24704097 | 1.00 | CNR2 (0.94) | CNR2CNR1TRPM8LDHAPPARG | |
| SCHEMBL13214131 | 1.00 | CNR2 (0.94) | CNR2CNR1TRPM8LDHAPPARG | |
| SCHEMBL29647762 | 1.00 | CNR2 (0.94) | CNR2CNR1TRPM8LDHAPPARG | |
| Delta9-Tetrahydrocannabinolic Acid A SCHEMBL29610699 | 0.97 | CNR2 (1.00) | CNR2CNR1TRPM8LDHAPPARG | |
| Delta9-Tetrahydrocannabinolic Acid A SCHEMBL16769847 | 0.97 | CNR2 (1.00) | CNR2CNR1TRPM8LDHAPPARG | |
| Delta9-Tetrahydrocannabinolic Acid A SCHEMBL18095976 | 0.97 | CNR2 (1.00) | CNR2CNR1TRPM8LDHAPPARG | |
| Delta9-Tetrahydrocannabinolic Acid A SCHEMBL6856735 | 0.97 | CNR2 (1.00) | CNR2CNR1TRPM8LDHAPPARG | |
| Delta9-Tetrahydrocannabinolic Acid A SCHEMBL23076463 | 0.97 | CNR2 (1.00) | CNR2CNR1TRPM8LDHAPPARG | |
| Delta9-Tetrahydrocannabinolic Acid A SCHEMBL14773902 | 0.97 | CNR2 (1.00) | CNR2CNR1TRPM8LDHAPPARG | |
| Delta9-Tetrahydrocannabinolic Acid A SCHEMBL29691633 | 0.97 | CNR2 (1.00) | CNR2CNR1TRPM8LDHAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024112694-A1 | RECOMBINANT POLYPEPTIDES WITH PRENYLTRANSFERASE ACTIVITY FOR BIOSYNTHESIS OF CANNABINOIDS AND HOP COMPOUNDS | WILLOW BIOSCIENCES, INC. (CA) | 2024-05-30 | — | — | WO | disclosed |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | KADDURAH DAOUK RIMA F (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | KADDURAH DAOUK RIMA F (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230340555-A1 | PRODUCTION OF GLYCOSYLATED CANNABINOIDS | WILLOW BIOSCIENCES, INC. (CA) | 2023-10-26 | — | — | US | disclosed |
| WO-2023205404-A2 | BIOSYNTHESIS OF CYCLOLAVANDULYL DERIVATIVES OF AROMATIC COMPOUNDS | INVIZYNE TECHNOLOGIES, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230279449-A1 | COMPOSITIONS AND METHODS FOR ENHANCING RECOMBINANT BIOSYNTHESIS OF CANNABINOIDS | WILLOW BIOSCIENCES, INC. (CA) | 2023-09-07 | — | — | US | disclosed |
| WO-2023133483-A1 | RECOMBINANT POLYPEPTIDES WITH BERBERINE BRIDGE ENZYME ACTIVITY USEFUL FOR THE BIOSYNTHESIS OF CANNABINOIDS | INVIZYNE TECHNOLOGIES, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20230193329-A1 | Compositions and Methods for Recombinant Biosynthesis of Cannabinoids | WILLOW BIOSCIENCES, INC. (CA) | 2023-06-22 | — | — | US | disclosed |
| US-20230193329-A1 | Compositions and Methods for Recombinant Biosynthesis of Cannabinoids | WILLOW BIOSCIENCES, INC. (CA) | 2023-06-22 | — | — | US | disclosed |
| WO-2023069921-A1 | RECOMBINANT THCA SYNTHASE POLYPEPTIDES ENGINEERED FOR ENHANCED BIOSYNTHESIS OF CANNABINOIDS | EPIMERON USA, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023010083-A2 | RECOMBINANT PRENYLTRANSFERASE POLYPEPTIDES ENGINEERED FOR ENHANCED BIOSYNTHESIS OF CANNABINOIDS | WILLOW BIOSCIENCES, INC. (CA) | 2023-02-02 | — | — | WO | disclosed |
| US-20220403349-A1 | PRENYLTRANSFERASE VARIANTS WITH INCREASED THERMOSTABILITY | INVIZYNE TECHNOLOGIES, INC. (US) | 2022-12-22 | — | — | US | disclosed |
| US-11518983-B1 | Prenyltransferase variants with increased thermostability | INVIZYNE TECHNOLOGIES, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| US-20220186231-A1 | RECOMBINANT ACYL ACTIVATING ENZYME (AAE) GENES FOR ENHANCED BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS | WILLOW BIOSCIENCES, INC. (CA) | 2022-06-16 | — | — | US | disclosed |
| WO-2022125960-A1 | RECOMBINANT ACYL ACTIVATING ENZYME (AAE) GENES FOR ENHANCED BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS | WILLOW BIOSCIENCES, INC. (CA) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022099078-A1 | PRODUCTION OF GLYCOSYLATED CANNABINOIDS | WILLOW BIOSCIENCES, INC. (CA) | 2022-05-12 | — | — | WO | disclosed |
| WO-2021222288-A1 | COMPOSITIONS AND METHODS FOR ENHANCING RECOMBINANT BIOSYNTHESIS OF CANNABINOIDS | WILLOW BIOSCIENCES, INC. (CA) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021195517-A2 | COMPOSITIONS AND METHODS FOR RECOMBINANT BIOSYNTHESIS OF CANNABINOIDS | WILLOW BIOSCIENCES, INC. (CA) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021163023-A1 | STABLE FORMULATIONS OF DRONABINOL | TRYAGx Labs Inc. (US) | 2021-08-19 | — | — | WO | disclosed |
| US-20210251947-A1 | STABLE FORMULATIONS OF DRONABINOL | TRYAGx Labs Inc. | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210251947-A1 | STABLE FORMULATIONS OF DRONABINOL | CNR2, CNR1, GPR18 | CNR2 1/4885CNR1 2/4885TRPM8 377/4885 |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | SLC25A20, CPT2, NDUFAB1 | CNR2 91/4885CNR1 106/4885TRPM8 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.